Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.
Dutt M, Hartel G, Richards RS, Shah AK, Mohamed A, Apostolidou S, Gentry-Maharaj A; Australian Ovarian Cancer Study Group; Hooper JD, Perrin LC, Menon U, Hill MM. Dutt M, et al. Among authors: perrin lc. Proteomics Clin Appl. 2023 Jul;17(4):e2200114. doi: 10.1002/prca.202200114. Epub 2023 Jun 1. Proteomics Clin Appl. 2023. PMID: 37147936 Free PMC article.
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group; Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. Helland Å, et al. PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064. PLoS One. 2011. PMID: 21533284 Free PMC article.
Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context.
Samoylovich A, Jennings B, Shannon C, Coward JI, Lourie R, Riordan J, Lai NA, van Driel WJ, Cabraal N, Jagasia N, Chetty N, Naidu S, Perrin LC, Barry SC. Samoylovich A, et al. Among authors: perrin lc. Aust N Z J Obstet Gynaecol. 2023 Oct;63(5):702-708. doi: 10.1111/ajo.13694. Epub 2023 May 31. Aust N Z J Obstet Gynaecol. 2023. PMID: 37259677
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.
He Y, Khan T, Kryza T, Jones ML, Goh JB, Lyons NJ, Pearce LA, Lee MD, Gough M, Rogers R, Davies CM, Gilks CB, Hodgkinson T, Lourie R, Barry SC, Perrin LC, Williams CC, Puttick S, Adams TE, Munro TP, Hooper JD, Chetty N. He Y, et al. Among authors: perrin lc. Mol Pharm. 2021 Sep 6;18(9):3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401. Epub 2021 Aug 27. Mol Pharm. 2021. PMID: 34448393
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Brennan D, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, GraemeWalker, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Janda M, et al. Among authors: perrin lc. Gynecol Oncol. 2021 Aug;162(2):526. doi: 10.1016/j.ygyno.2021.05.016. Epub 2021 May 28. Gynecol Oncol. 2021. PMID: 34053746 Free article. No abstract available.
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Janda M, et al. Among authors: perrin lc. Gynecol Oncol. 2021 Apr;161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029. Gynecol Oncol. 2021. PMID: 33762086 Free article. Clinical Trial.
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Among authors: perrin lc. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Harrington BS, He Y, Khan T, Puttick S, Conroy PJ, Kryza T, Cuda T, Sokolowski KA, Tse BW, Robbins KK, Arachchige BJ, Stehbens SJ, Pollock PM, Reed S, Weroha SJ, Haluska P, Salomon C, Lourie R, Perrin LC, Law RHP, Whisstock JC, Hooper JD. Harrington BS, et al. Among authors: perrin lc. Theranostics. 2020 Jan 12;10(5):2095-2114. doi: 10.7150/thno.30736. eCollection 2020. Theranostics. 2020. PMID: 32104500 Free PMC article.
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
Nguyen THM, Carreira PE, Sanchez-Luque FJ, Schauer SN, Fagg AC, Richardson SR, Davies CM, Jesuadian JS, Kempen MHC, Troskie RL, James C, Beaven EA, Wallis TP, Coward JIG, Chetty NP, Crandon AJ, Venter DJ, Armes JE, Perrin LC, Hooper JD, Ewing AD, Upton KR, Faulkner GJ. Nguyen THM, et al. Among authors: perrin lc. Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090. Cell Rep. 2018. PMID: 29949758 Free article.
43 results